A phase I, open-label, single-dose, mass balance study of 14C-labeled abiraterone acetate in healthy male subjects

Xenobiotica

Volumn 43, Issue 4, 2013, Pages 379-389

  Acharya, Milin ^a   Gonzalez, Martha ^a   Mannens, Geert ^b   De Vries, Ronald ^b   Lopez, Christian ^a   Griffin, Thomas ^a   Tran, NamPhuong ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Abiraterone; Disposition; Human; Metabolites; Prostate cancer

Indexed keywords

ABIRATERONE; ABIRATERONE ACETATE; ABIRATERONE SULFATE; CARBON 14; DRUG METABOLITE; N OXIDE ABIRATERONE SULFATE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BODY MASS; CLINICAL ARTICLE; CONCENTRATION RESPONSE; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG EXPOSURE; DRUG METABOLISM; DRUG SAFETY; FECES ANALYSIS; HUMAN; MALE; NORMAL HUMAN; OPEN STUDY; PHASE 1 CLINICAL TRIAL; RADIOACTIVITY; SINGLE DRUG DOSE; URINALYSIS; URINARY EXCRETION;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANDROSTENOLS; CARBON RADIOISOTOPES; DOSE-RESPONSE RELATIONSHIP, DRUG; HEALTH; HUMANS; MALE; METABOLIC NETWORKS AND PATHWAYS; METABOLOMICS; MIDDLE AGED; RADIOACTIVITY; TIME FACTORS; YOUNG ADULT;

EID: 84879544480     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2012.721022     Document Type: Article

References (10)

1. Acharya M, Bernard A, Gonzalez M, Jiao J, De Vries R, Tran N. (2012). Open-label, phase I, pharmacokinetic studies of abiraterone acetate in healthy men. Cancer Chemother Pharmacol 69:1583-1590
2. Attard G, Reid AH, A'Hern R, Parker C, Oommen NB, Folkerd E, Messiou C, Molife LR, Maier G, Thompson E, Olmos D, Sinha R, Lee G, Dowsett M, Kaye SB, Dearnaley D, Kheoh T, Molina A, de Bono JS. (2009). Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 27:3742-3748
3. Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S, Barrett M, Parker C, Martins V, Folkerd E, Clark J, Cooper CS, Kaye SB, Dearnaley D, Lee G, de Bono JS. (2008). Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 26:4563-4571
4. Chan FC, Potter GA, Barrie SE, Haynes BP, Rowlands MG, Houghton J, Jarman M. (1996). 3- and 4-pyridylalkyl adamantanecarboxylates: Inhibitors of human cytochrome P450(17 alpha) (17 alphahydroxylase/C17,20-lyase). Potential nonsteroidal agents for the treatment of prostatic cancer. J Med Chem 39:3319-3323 (Pubitemid 26322857)
5. Danila DC, Morris MJ, de Bono JS, Ryan CJ, Denmeade SR, Smith MR, Taplin ME, Bubley GJ, Kheoh T, Haqq C, Molina A, Anand A, Koscuiszka M, Larson SM, Schwartz LH, Fleisher M, Scher HI. (2010). Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castrationresistant prostate cancer. J Clin Oncol 28:1496-1501
6. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Flhon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI; COU-AA-301 Investigators. (2011). Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:1995-2005
7. Hakki T, Bernhardt R. (2006). CYP17- and CYP11B-dependent steroid hydroxylases as drug development targets. Pharmacol Ther 111:27-52 (Pubitemid 43765541)
8. Kohli M, Tindall DJ. (2010). New developments in the medical management of prostate cancer. Mayo Clin Proc 85:77-86
9. Reid AH, Attard G, Danila DC, Oommen NB, Olmos D, Fong PC, Molife LR, Hunt J, Messiou C, Parker C, Dearnaley D, Swennenhuis JF, Terstappen LW, Lee G, Kheoh T, Molina A, Ryan CJ, Small E, Scher HI, de Bono JS. (2010). Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 28:1489-1495
10. Ryan CJ, Smith MR, Fong L, Rosenberg JE, Kantoff P, Raynaud F, Martins V, Lee G, Kheoh T, Kim J, Molina A, Small EJ. (2010). Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol 28:1481-1488